Overview

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Status:
Recruiting

Trial end date:
2025-05-02

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the superiority in efficacy of abatacept compared with adalimumab, on background methotrexate, in adults with early, seropositive, and shared epitope-positive rheumatoid arthritis and an inadequate methotrexate response.

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Abatacept
Adalimumab
Methotrexate